| scholarly article | Q13442814 |
| P2093 | author name string | Jancinová V | |
| Nosál R | |||
| Petríková M | |||
| P433 | issue | 5 | |
| P921 | main subject | platelet aggregation | Q14913634 |
| chloroquine | Q422438 | ||
| P304 | page(s) | 495-504 | |
| P577 | publication date | 1994-06-01 | |
| P1433 | published in | Thrombosis Research | Q15758741 |
| P1476 | title | On the inhibitory effect of chloroquine on blood platelet aggregation | |
| P478 | volume | 74 |
| Q94453583 | Antimalarial drugs impact chemical messenger secretion by blood platelets |
| Q34604474 | Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit |
| Q34129797 | Antimalarials. |
| Q37721617 | Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet? |
| Q53093982 | Antithrombotic treatment for stroke associated with antiphospholipid antibodies. |
| Q41933743 | Blood platelets and chloroquine |
| Q41928539 | Chloroquine minimizes sampling artefacts for radioimmunological determination of thromboxane B2 in plasma |
| Q39807701 | Chloroquine stimulates nitric oxide synthesis in murine, porcine, and human endothelial cells |
| Q41929179 | Chloroquine, quinine and quinidine inhibit calcium release from macrophage intracellular stores by blocking inositol 1,4,5-trisphosphate binding to its receptor |
| Q41921622 | Chloroquine: a multipotent inhibitor of human platelets in vitro |
| Q54218397 | Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. |
| Q34161393 | Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort |
| Q97535589 | Hydroxychloroquine and Covid-19: A Cellular and Molecular Biology Based Update |
| Q39144641 | Hydroxychloroquine's Efficacy as an Antiplatelet Agent Study in Healthy Volunteers: A Proof of Concept Study |
| Q41934841 | Hydroxychloroquine: a new therapeutic approach to the thrombotic manifestations of antiphospholipid syndrome |
| Q39608521 | Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome |
| Q89603158 | Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology |
| Q37404485 | New approaches for managing antiphospholipid syndrome |
| Q53495449 | Novel therapies for the antiphospholipid syndrome. |
| Q37704593 | Revisiting the molecular mechanism of neurological manifestations in antiphospholipid syndrome: beyond vascular damage |
| Q34498515 | Systemic lupus erythematosus: review of synthetic drugs |
| Q48081474 | The chequered history of the antiphospholipid syndrome. |
| Q41920531 | The effects of chloroquine on bleeding time and disappearance of platelet 5-hydroxytryptamine in rabbits |
| Q94672281 | The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis? |
Search more.